Some takes and thoughts from @adamfeuerstein on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.
Comments
(ーー゛)
There's nothing here…
Some takes and thoughts from @adamfeuerstein on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.